Sprycel and Wakix

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Dasatinib has the potential to prolong the QT interval. In addition, limited data suggest that pitolisant may produce mild to moderate QT interval prolongation (10 to 13 milliseconds) at doses 3 to 6 times the standard therapeutic dose. Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In single-arm clinical studies involving patients with leukemia treated with dasatinib, the mean QTc interval changes from baseline using Fridericia's method (QTcF) were 3 to 6 msec; the upper 95% confidence intervals for all mean changes from baseline were less than 8 msec. Nine patients had QTc prolongation reported as an adverse event, three of whom (less than 1%) experienced a QTcF greater than 500 msec. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drugs. Furthermore, coadministration with pitolisant may reduce plasma concentrations and therapeutic effects of CYP450 3A4 substrates such as dasatinib. The proposed mechanism is induction of this isoenzyme by pitolisant and its main metabolite, and is based on in vitro data. However, clinical data are not available. MANAGEMENT: Concomitant use of multiple agents associated with QT interval prolongation should generally be avoided. In addition, the manufacturer advises that the concomitant use of pitolisant with narrow therapeutic index drugs (e.g., kinase inhibitors) that are CYP450 3A4 substrates should also be avoided, if possible. Clinical and laboratory parameters should be monitored if these drugs are coadministered, and patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. References "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA. "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 View all 4 references

GENERALLY AVOID: Dasatinib has the potential to prolong the QT interval. In addition, limited data suggest that pitolisant may produce mild to moderate QT interval prolongation (10 to 13 milliseconds) at doses 3 to 6 times the standard therapeutic dose. Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In single-arm clinical studies involving patients with leukemia treated with dasatinib, the mean QTc interval changes from baseline using Fridericia's method (QTcF) were 3 to 6 msec; the upper 95% confidence intervals for all mean changes from baseline were less than 8 msec. Nine patients had QTc prolongation reported as an adverse event, three of whom (less than 1%) experienced a QTcF greater than 500 msec. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drugs. Furthermore, coadministration with pitolisant may reduce plasma concentrations and therapeutic effects of CYP450 3A4 substrates such as dasatinib. The proposed mechanism is induction of this isoenzyme by pitolisant and its main metabolite, and is based on in vitro data. However, clinical data are not available.

MANAGEMENT: Concomitant use of multiple agents associated with QT interval prolongation should generally be avoided. In addition, the manufacturer advises that the concomitant use of pitolisant with narrow therapeutic index drugs (e.g., kinase inhibitors) that are CYP450 3A4 substrates should also be avoided, if possible. Clinical and laboratory parameters should be monitored if these drugs are coadministered, and patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

Sprycel

Generic Name: dasatinib

Brand name: Sprycel

Synonyms: n.a.

What is Sprycel?

Wakix

Generic Name: pitolisant

Brand name: Wakix

Synonyms: Wakix Tablets

What is Wakix?